Cloverleaf Bio Secures $33 Million in Seed Funding to Advance RNA Therapeutics for Cancer

Cloverleaf Bio Raises $33 Million in Seed Funding

Cloverleaf Bio, a company based in New Haven, Connecticut, has announced that it has raised $33 million in a seed funding round. The company is focused on developing a new class of RNA therapeutics aimed at transforming cancer treatment.

Investors and Leadership

The seed round was led by 4BIO Capital, with participation from several high-profile investors including AbbVie Ventures, Eli Lilly, Boehringer Ingelheim Venture Fund, Draper Associates, Mission BioCapital, and the American Cancer Society. The company was co-founded by Cole Lewis and Austin Draycott, who are both integral to its leadership.

Use of Funds

While specific details on the use of the funds were not disclosed, it is anticipated that the investment will support the further development of Cloverleaf Bio's RNA-based therapies, potentially accelerating their path to clinical trials and regulatory approval.

About Cloverleaf Bio

Cloverleaf Bio is pioneering the development of RNA therapeutics with the potential to revolutionize the way cancer is treated. By focusing on RNA-based solutions, the company aims to provide more effective, targeted treatments for patients.

For more information about Cloverleaf Bio and their groundbreaking work in RNA therapeutics, visit their website.